Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29435116 | 0.98 | ESR1 (0.52) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL3497043 | 0.90 | MAPT (0.52) | TSHRALDH1A1MAPTKMT2AAPP | |
| SCHEMBL4664901 | 0.83 | SRD5A2 (0.54) | TYRLMNATSHRALDH1A1MAPT | |
| SCHEMBL7753912 | 0.83 | ESR1 (0.56) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL20732295 | 0.82 | ESR1 (0.50) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL76790 | 0.81 | ESR1 (0.54) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL1107163 | 0.81 | TSHR (0.50) | LMNATSHRALDH1A1MAPTKMT2A | |
| SCHEMBL7067690 | 0.81 | ESR1 (0.54) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL13313605 | 0.81 | ESR1 (0.54) | ESR1ESR2CYP3A4TYRLMNA | |
| SCHEMBL6571 | 0.80 | MAPT (0.67) | ESR1ESR2CYP3A4TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4827845-A | FROM PHENOL OR ARYL ETHER, KETONE, CARBON MONOXIDE, ACID | ASHLAND OIL, INC. (US) | 1989-05-09 | — | — | US | claimed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025224463-A1 | DESMURAMYLPEPTIDE ANALOGUE MONOESTER | Imhotex Limited (GB) | 2025-10-30 | — | — | WO | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024224089-A1 | DESMURAMYLPEPTIDE MONOESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024224086-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| US-6887952-B1 | N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use | BIOSITE, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6043284-A | ACYL COENZYME A: CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | GLAXO WELLCOME INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5776951-A | ANTICHOLESTEROL AGENT | GLAXO WELLCOME INC. (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0706508-A1 | ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001326-A1 | ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-12 | — | — | WO | disclosed |
| US-4827845-A | FROM PHENOL OR ARYL ETHER, KETONE, CARBON MONOXIDE, ACID | ASHLAND OIL, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| US-4827845-A | FROM PHENOL OR ARYL ETHER, KETONE, CARBON MONOXIDE, ACID | ASHLAND OIL, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| US-4080471-A | ANTIARRYTHMIA | AKTIEBOLAGET HASSLE (SW) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | ESR1 3024/4885ESR2 1445/4885CYP3A4 1340/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR1 3024/4885ESR2 1445/4885CYP3A4 1340/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ESR1 3024/4885ESR2 1445/4885CYP3A4 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.